Navigation Links
A step forward in the treatment of chronic urticaria
Date:3/20/2013

This press release is available in Spanish.

Barcelona, 20th March 2013.- An international study involving dermatologists from the Hospital del Mar and Spanish subjects has concluded that a drug normally used to treat severe bronchial asthma caused by allergies (Omalizumab) rapidly eliminates the symptoms of spontaneous chronic urticaria, a development that it is expected will significantly improve the quality of life of chronic urticaria sufferers.

Spontaneous chronic urticaria, one of the most common skin diseases, consists of an abrupt reaction that results in hives or stains of different shapes and sizes on the surface of the skin that grow and produce a very intense itch. Sufferers can develop dozens of hives each day for months or years. When the condition persists for more than 6 weeks, it is referred to as chronic urticaria and can last between approximately 5 and 10 years, adversely affecting the quality of life of the sufferer in both physical and emotional terms.

Approximately 50% of urticaria patients do not respond to treatment with standard doses of non-sedative antihistamines, and require a heavier dose of antihistamines. Some people even require immunosupressors, such as corticoids and cyclosporine A, to control the condition. These immunosupressors have significant side effects.

The study, in which Dr. Ana Gimnez Arnau, a dermatologist at the Hospital del Mar and researcher with the group conducting research on inflammatory dermatological diseases at the IMIM (Hospital del Mar Medical Research Institute) was involved alongside institutions from Germany, the United States, and the United Kingdom, demonstrated that Omalizumab, a biological treatment that prevents immunoglobulin E from joining up with the receptor of the cells that triggers the urticaria, the mast cell, radically eliminates clinical symptoms (itching) and signs of ur
'/>"/>

Contact: Marta Calsina
mcalsina@imim.es
34-933-160-680
IMIM (Hospital del Mar Medical Research Institute)
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Corporate Whistle Blower Center Now Urges Insiders to Step Forward if They Have Proof a Medical Device Maker Knew About Failures & Continued to Sell the Product-Rewards
2. Corporate Whistle Blower Center Now Urges Employees of Any Type Of Private Contractor in Afghanistan or Iraq to Step Forward for Rewards if They Possess Proof of Fraud
3. Retina Specialty Institute Gives Patients Something to Look Forward to in Crestview
4. DePuy ASR Hip Recall, Transvaginal Mesh Lawsuit Updates: Bernstein Liebhard LLP Looks Forward to Start of First Bellwether Trials in New Year
5. Propecia Lawsuits Being Investigated by Bernstein Liebhard LLP, as Propecia Litigation Pending in New Jersey Superior Court Continues to Move Forward
6. Massage School San Diego Names Step Forward Pick of the Week as RAW One
7. Rectal microbicide research takes giant leap forward with groundbreaking educational video
8. Attorney Deborah Truhowsky Featured On “Paying It Forward” Internet Broadcast Program
9. GiveForward.com Helps Launch Online Campaign to Help Sick Single Mom in Need
10. University of Pennsylvania Medicine receives National Institutes of Health grant to help local communities move forward after asbestos exposure
11. A leap forward in the quest to develop an artificial pancreas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... That’s right, ... are the STASH awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) ... well as tried-and-true products that have stood the test of time. These include ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source ... in Chicago at Grant Park. The festival will end on Sunday, August 2nd. ... Chicago for the annual Lollapalooza. This unique and unbelievably popular festival attracts the ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival ... Zeltiq Aesthetics released this new applicator in the United States as an upgrade to ... thighs. The original applicator required a 2 hour treatment time. The new ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of ... three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology ... from MDLinx makes preparing for the exam easy and painless. MDLinx offers thousands ...
(Date:7/31/2015)... New York (PRWEB) , ... ... ... trial attorney Jason T. Brown’s live lecture on pharmaceutical negligence is now ... 28th, 2015 was well received with a 94% approval rating from the ...
Breaking Medicine News(10 mins):Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2
... Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- Nicotine patches ... women quit smoking, a new study finds. Dr. Tim ... University of Nottingham in England, and colleagues assigned 1,050 women ... two groups. Members of one group received behavioral smoking cessation ...
... substantial amount of trans fats are more likely than their ... However, the risk of stroke associated with trans ... the findings from University of North Carolina at Chapel Hill ... Ischemic Stroke Among Postmenopausal Women," was published Thursday (March 1, ...
... the severe symptoms of a life-threatening bone marrow cancer called ... according to a phase III clinical trial published in the ... . "The Phase I/II clinical trial showed that ruxolitinib ... now this phase III study indicates that the drug extends ...
... Many leading causes of death are linked to ... in minority populations have lower levels of physical ... to the Department of Health & Human Services. ... found that minority adults who received exercise interventions ...
... (HealthDay News) -- Children with a depressed father are more ... Most prior research has focused on depressed mothers and ... to the researchers from the NYU School of Medicine. ... households. About 25 percent of kids whose mother and father ...
... Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- Patients who ... are less likely to develop depression than those not on ... Dr. Mary Whooley of the San Francisco VA Medical ... patients for depression. The researchers found those taking statins were ...
Cached Medicine News:Health News:Nicotine Patches May Not Help During Pregnancy 2Health News:Nicotine Patches May Not Help During Pregnancy 3Health News:Aspirin may counteract potential trans fat-related stroke risk in older women 2Health News:Drug improves survival and quality of life for people with myelofibrosis 2Health News:Drug improves survival and quality of life for people with myelofibrosis 3Health News:Fitness programs for minority adults lack cultural relevance, MU study finds 2Health News:Dad's Depression May Rub Off on Child's Behavior 2Health News:Could a Statin Lower Your Risk for Depression? 2Health News:Could a Statin Lower Your Risk for Depression? 3
(Date:7/31/2015)... -- Semler Scientific, Inc. (Nasdaq: SMLR ), a company ... and physician groups, today reported financial results for the ... "In the second quarter of 2015, Semler reported continued ... quarter over quarter revenue growth of 8%, and quarter ... units of 18%," said Doug Murphy-Chutorian, M.D., chief executive ...
(Date:7/31/2015)... India , July 31, 2015 ... CRM solutions for video, data and cloud computing ... with a leading pharma giant for Internet of ... different IoT applications offered on subscription model. ... Pharma giant is striving for business innovations ...
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 /PRNewswire/ ... that it will release its second quarter 2015 financial ... 6, 2015.   In conjunction with the release, the ... community at 5:00 p.m. Eastern Time on ... results of the quarter and other business developments. ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2
... BETHESDA, Md., May 14 Spherix Incorporated (Nasdaq: ... for diabetes therapy, and a provider of technical ... and pharmaceutical companies, today announced that, on May ... new, independent Director, Thomas B. Peter, to begin ...
... in ACR20 responses over placeboPRINCETON, N.J., May 14 ... today announced that the MDX-1100 Phase 2 proof-of-concept ... receiving methotrexate successfully met its primary endpoint. The ... randomized, double-blind, placebo-controlled Phase 2 trial indicated that ...
Cached Medicine Technology:Spherix Elects New Independent Director, and Elects Chairman of the Board 2Spherix Elects New Independent Director, and Elects Chairman of the Board 3Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis 2Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis 3Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis 4
The Trident ceramic acetabular system provides several important benefits and meets greater demands of younger, more active patients....
Optimal solution for normal acetabulum and younger patients....
The Biopro Cox comb cup is manufactured from titanium and is porous coated on the outside of the shell. The Cox comb cup accommodates a polyethylene insert....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
Medicine Products: